Гинекология (Jun 2017)
Clinical-economic rational of using of prolonged gonadotropin in IVF programs in according to the new opportunities of corifollitropin alfa
Abstract
Purpose. To define the schemes of induction of superovulation, what are the most pharmacoeconomical founded. Methods. Pharmacoeconomic analysis was performed using the cost minimization analysis on the assumption of equal effectiveness compared schemes of hormonal stimulation, which was confirmed in the review of clinical trials and meta-analysis. To estimate the cost of drugs for ovulation induction we used registered VED rates and recommended in the instructions for medical use and the standard of care for infertility using assisted reproductive technologies dosing regimens. Results. The results of the pharmacoeconomic analysis in according to all scenarios of the initial data, confirmed the pharmacoeconomic advantage of using corifollitropin alfa in comparison with the rFSH (follitropin alfa): 1) 1 732.22 rubles, approximately 5%; 2) 3 269.44 rubles, approximately 7%; 3) 14 955.83 rubles, approximately 30%. Conclusions. The scheme of hormonal stimulation using corifollitropin alfa in according to all scenarios of the initial data is more pharmacoeconomical reasonable, since it economizes the direct of medical costs with comparable efficacy, fewer subcutaneous injections, and the possibility to decrease the duration of stimulation cycle as compared with daily rFSH.
